Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 3/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | SCD | O00767 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964524 | 0.86 | DRD2 (0.75) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL1545611 | 0.85 | ACHE (0.93) | ACHEDRD2SLC6A4HTR2AHTR1A | |
| SCHEMBL6182384 | 0.83 | ACHE (0.80) | ACHEDRD2SLC6A4HTR2AHTR1A | |
| SCHEMBL13898738 | 0.83 | DRD2 (0.67) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL18432239 | 0.83 | DRD2 (0.82) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL10637057 | 0.83 | ACHE (0.65) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL7353484 | 0.83 | ACHE (0.76) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL1545202 | 0.82 | ACHE (0.57) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL14282332 | 0.82 | ACHE (0.74) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL3122834 | 0.81 | ACHE (0.77) | ACHEDRD2SLC6A4HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303877-B1 | PROCESS TO PREPARE PALIPERIDONE AND INTERMEDIATES THEREOF | INKE SA (ES) | 2017-02-15 | — | — | EP | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | ACHE 390/4885DRD2 1277/4885SLC6A4 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.